Ipsen shares slip after cancer drug Tazverik withdrawal

Ipsen SA

09/03/2026 09:22

** Shares in Ipsen IPN.PA  fall around 3% after it withdrew Tazverik medicine from all markets following disappointing trial data

** J.P. Morgan sees the move as disheartening as it estimates the value of the cancer drug to Ipsen shares at about EUR 2/share

     ** Jefferies calls it a "minor setback" as management had already lowered sales guidance and it viewed the trial as high risk

** Jefferies expects the shares to decline by more than the 2% net present value tied to Tazverik, noting that sentiment and the stock’s recent outperformance could deepen the hit

** Up to the previous session's close, shares were up 35.2%​ YTD - LSEG data

($1 = 0.8677 euros)

(Reporting by Jakob Van Calster)

((jakob.vancalster@thomsonreuters.com ))